PEPTIDE

Teriparatide (PTH 1-34, Forteo)

Daily SC PTH(1-34); intermittent exposure activates PTH1R for net bone formation, increasing BMD and reducing fracture risk.

BIOGATE · GREEN | POSTERIOR 61.5% | MW 4117.7 | 34AA

SEQUENCE

SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF

Modifications: recombinant N-terminal PTH(1-34)

PDA-V1 chain of custody

Outer hash

455-c8400465c8593475c8726485c88b9495c8a4c4a5c8bdf4b5c8d724c

Merkle root

b36f9475b26f92e2b16f914fb06f8fb-caf6f8e29ae6f8c96ad6f8b03ac6f8970

Inputs

7-c1454807d1456137e1457a67f14593980145acc81145c5f82145df2

TEE attestation

7-fafb51f7eafb38c81afb84580afb6b27bafaed37aafad407dafb1f97cafb066

Living Outcome Oracle

± =52.4 ² =32.8 **P(success) = 61.5%**

95% CI [49.5%, 73.5%]

Seven-rule export gate

7 / 7 rules satisfied · audience: researcher · Full attestation set, raw posteriors, all hashes

- Grade A or B citation present on the core claim
- BioGate verdict is GREEN or AMBER (RED/BLACK refused)
- Jurisdiction permits the audience-appropriate use
- RWE summary attached when claim depends on outcome data
- Prediction-outcome pairs disclosed when posterior cited
- No human-use claim beyond cited indications
- COA registry lookup available for any synthesis claim

Citations

GRADE A — 2001 · N Engl J Med

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women

Neer RM et al.

PMID 11346808